DelSiTech

DelSiTech is an innovative drug delivery and development company that works with its partners to turn their active agents into novel, viable therapeutics.

[DelSiTech @DelSiTech]

We are honored to be recognized again with the "Growth in Sight" award. The award acknowledges @DelSiTech potential for growth and the positive impact we have on the growth and development of our community. Read more: https://t.co/B8tL9zxSxq

[DelSiTech @DelSiTech]

@DelSiTech is hosting a webinar on the long-acting injectable landscape. Prof. René Holm of the University of Southern Denmark, Dr. Peter Markland of Tolmar Pharmaceuticals, and Dr. Jokinen Mika will provide their unique perspectives.
Register free here: https://t.co/NWK4y0a3jI

[DelSiTech @DelSiTech]

@DelSiTech is thrilled to announce an exclusive licensing agreement with a leading global pharmaceutical company! Under the terms of the agreement, #DelSiTech will receive $9M and potential milestone payments exceeding $200M, plus royalties on net sales. https://t.co/VUH2Fgkvhl

[DelSiTech @DelSiTech]

@DelSiTech is thrilled to announce a global license and development agreement with @Tolmar, marking a significant milestone in our partnership since their investment in January 2024.

Read more here: https://t.co/zowruFJ1zY
#DelSiTech #drugdevelopment #SilicaMatrix

[DelSiTech @DelSiTech]

@DelSiTech we are pleased to announce the successful completion of a EUR 10 million financing round, the largest single financing round in the Company’s history. More information can be found here: https://t.co/EOI2E6LhKL #drugdelivery #financing

[DelSiTech @DelSiTech]

As winter arrives, we find ourselves reflecting on this autumns successful events. Thank you to all of our partners for their support and dedication to development of long-acting therapies this year at Bio Europe. #bioeurope

[DelSiTech @DelSiTech]

@DelSiTech is excited to announce positive topline clinical data from a phase 1 trial for our sustained release eye drop platform. Find out more at https://t.co/cSEtovKq3l #Eyecare

[DelSiTech @DelSiTech]

@DelSiTech is pleased to announce completion of a cleanroom facility for aseptic manufacturing! The state of the art facility will continue to accelerate the development of important treatments for both us and our partners. Find out more at https://t.co/cSEtovKq3l
#healthcare

[DelSiTech @DelSiTech]

@DelSiTech is proud to announce a new collaboration with the Gates Foundation for the development of sustained release human immunodeficiency virus (HIV) vaccines. Read more at https://t.co/G0G41aVUVb
#HIVAids #globalhealth

[DelSiTech @DelSiTech]

@DelSiTech will be attending CPHI Frankfurt. If you would like to discuss more on long-acting controlled release formulations please contact us here https://t.co/ErMvnezWze

[DelSiTech @DelSiTech]

@DelSiTech is proud to announce approval to start a first-in-man clinical study with its in-house controlled-release eye drops utilizing Silica Matrix technology. The unique technology is applicable for both injectable and topical ophthalmic delivery. https://t.co/pOxxhN347l

[DelSiTech @DelSiTech]

@DelSiTech is exited to participate the 22nd Euretina Congress. Silica Matrix delivery platform offers unique solutions to extend the durability of treatment for both, topical ophthalmic and IVT delivery. If you want to discuss more, please contact us here
https://t.co/ymt8uIul4F

[DelSiTech @DelSiTech]

@DelSiTech is excited to announce a new exclusive agreement with Iveric Bio, Inc. Read more here https://t.co/mcXkoAKnsE #Ophthalmology #Pharmaceuticals

[DelSiTech @DelSiTech]

@DelSiTech was happy to be at #DDF2022. We made many new connections and met with old acquaintances. Our presentation on subcutaneous and ophthalmic delivery for both topical and intra-ocular was well received. Please contact us here for more https://t.co/tW4TcXkfIN

[DelSiTech @DelSiTech]

@DelSiTech we are enthusiastic for finally being physically present at #BIO22. If you are facing challenges in drug delivery, please contact us here: https://t.co/fYi0YRw3Hn

[DelSiTech @DelSiTech]

@DelSiTech is excited to participate #ARVO2022 with a poster on extended 24-h topical release from a single eye drop. Feel free to stop by our poster and discuss more about Silica Matrix drug delivery. Please contact us here for arranging a meeting https://t.co/9PDuCBPHiD

[DelSiTech @DelSiTech]

@DelSiTech is pleased to announce a new licensing deal with Optifye Therapeutics to develop a controlled release eye drop product. This deal will further solidify our presence as a drug developer for eye drops and presents the versatility of Silica Matrix https://t.co/KHHkJ4A1sh

[DelSiTech @DelSiTech]

@DelSiTech is pleased to welcome Mr. Kristian Rantala as our new CFO. He has over 20 years of experience in financial management including several CFO positions and he has previously participated in a successful Nasdaq IPO. https://t.co/IcR1X40HI0

[DelSiTech @DelSiTech]

@DelSiTech Ltd welcomes Dr. Outi Heikkilä, as the new Director, Head of Manufacturing. Her core competences include cleanroom operations, GMP manufacturing, and quality requirements of investigational medicinal products. Please read more at https://t.co/Q0sL51PrvD